NASDAQ · BCAX
Healthcare · Biotechnology
$8.96
Down-$0.15 (-1.67%)
Updated Nov 4, 2026, 5:01 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BCAX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BCAX closed at $8.96 after 21 trading sessions, down 45.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $8.03 | $9.48 | $7.90 | $8.96 | 2.33M |
| Nov 2, 2026 | $9.06 | $9.165 | $7.87 | $7.93 | 2.5M |
| Oct 30, 2026 | $9.38 | $9.38 | $8.36 | $9.13 | 4.2M |
| Oct 29, 2026 | $9.79 | $10.19 | $9.35 | $9.73 | 3.2M |
| Oct 28, 2026 | $17.37 | $17.57 | $8.90 | $9.76 | 15.42M |
| Oct 27, 2026 | $16.91 | $17.59 | $16.60 | $17.48 | 609.33K |
| Oct 26, 2026 | $16.98 | $17.67 | $16.44 | $16.89 | 1.05M |
| Oct 23, 2026 | $17.53 | $17.85 | $16.98 | $17.07 | 730.16K |
| Oct 22, 2026 | $17.92 | $18.07 | $17.15 | $17.61 | 816.94K |
| Oct 21, 2026 | $18.31 | $18.78 | $17.90 | $17.91 | 656.72K |
| Oct 20, 2026 | $17.79 | $18.645 | $17.31 | $18.35 | 493.42K |
| Oct 19, 2026 | $16.92 | $17.60 | $16.60 | $17.47 | 865.42K |
| Oct 16, 2026 | $17.60 | $17.78 | $16.69 | $16.78 | 820.02K |
| Oct 15, 2026 | $17.51 | $17.95 | $17.25 | $17.62 | 662.06K |
| Oct 14, 2026 | $17.23 | $17.68 | $17.11 | $17.34 | 1.43M |
| Oct 13, 2026 | $17.29 | $17.61 | $17.01 | $17.34 | 1.27M |
| Oct 12, 2026 | $17.46 | $17.99 | $17.11 | $17.33 | 659.11K |
| Oct 9, 2026 | $17.19 | $17.82 | $16.88 | $17.50 | 715.97K |
| Oct 8, 2026 | $16.32 | $17.33 | $15.85 | $17.26 | 1.25M |
| Oct 7, 2026 | $16.44 | $17.11 | $16.2464 | $16.42 | 915.6K |
| Oct 6, 2026 | $17.43 | $17.52 | $16.31 | $16.56 | 981.2K |
The latest Smart Investors Daily articles mentioning BCAX.
Company
Market Activity
Research & News
BCAX research
Company profile and research snapshot.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Goldman Sachs | Sell | — |
| Oct 29, 2026 | Wedbush | Outperform | — |
| Oct 19, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 12, 2026 | Morgan Stanley | Overweight | — |
Generated Nov 4, 2026, 3:09 PM
Bicara Therapeutics (BCAX) gained 0.56% today, a modest move likely driven by modest market momentum rather than company-specific catalysts. The stock appears to be riding broader market strength as several large-cap stocks moved higher on Tuesday.
Bottom line: BCAX's modest gain today appears to reflect general market strength rather than company-specific developments. The real catalyst to watch is the November 9th earnings and business update presentation, which will provide critical insights into the company's pipeline, financial position, and strategic direction—making it essential for investors to monitor.
Benzinga · Nov 3, 2026
U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.
Yahoo · Nov 2, 2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may r
Benzinga · Oct 30, 2026
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
Benzinga · Oct 29, 2026
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCAX.
